Ingredient or product comparison
Clinical Evidence vs Mechanistic Potential
The evidence base for GHK-Cu in telogen effluvium is weaker than for androgenetic alopecia. A 2007 study published in Advances in Therapy evaluated a copper-peptide complex (not pure GHK-Cu, but a proprietary blend) in 23 women with chronic telogen effluvium—4
This source-based comparison does not add ratings or recommend a winner.
- The evidence base for GHK-Cu in telogen effluvium is weaker than for androgenetic alopecia. A 2007 study published in Advances in Therapy evaluated a copper-peptide complex (not pure GHK-Cu, but a proprietary blend) in 23 women with chronic telogen effluvium—47% showed improvement in hair density by phototrichogram analysis after 12 weeks. That sounds promising until you read the methods: no control group, subjective self-assessment, and the formulation also contained panthenol and biotin, making it impossible to isolate GHK-Cu's effect.
- Here's the honest answer: the mechanistic rationale is strong—GHK-Cu's ability to reduce inflammatory cytokines and stimulate dermal papilla proliferation has been replicated in multiple in vitro studies. But translating that to human scalps is harder. Telogen effluvium isn't one condition—it's a symptom with dozens of potential triggers (thyroid dysfunction, iron deficiency, autoimmune flares, postpartum hormonal shifts). If the underlying trigger isn't resolved, GHK-Cu won't override it. If inflammation has already resolved and follicles are recovering naturally, GHK-Cu may accelerate the timeline—but proving that requires head-to-head placebo trials, which don't exist yet.
- Patients who respond best tend to have: (1) acute telogen effluvium (triggered event within the past 6 months), (2) no concurrent androgenetic alopecia (GHK-Cu doesn't block DHT), and (3) baseline scalp inflammation visible on dermoscopy (perifollicular erythema, trichodynia). If you're shedding 200+ hairs daily but your scalp feels normal and the trigger resolved 9 months ago, you're likely in natural recovery—GHK-Cu might shorten the regrowth phase from 6 months to 4, but the outcome would've been similar without it.